Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company that engages in the manufacturing of biopharmaceutical medicines in South Korea. The firm operates two business divisions: the Biomedical Division and the Biochemical Division. The firm derives key revenue from the Biochemical Division. The Biomedical Division focuses on the development of stem cell therapies as its core business. The Biochemical Division produces and sells electronic materials with excellent electrical properties (low dielectric constant, low dielectric loss), pharmaceutical intermediates such as nucleosides and mPEG, eco-friendly phosphorus-based flame retardants (for textiles and electronic materials), and other industrial fine chemical products.
Contact
874 Eonju-ro, Gangnam-gu
7th Floor, Ssangbong Building
Sinsa-dong
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
stocks
ASX listed media giant drives strong earnings growth
stocks
ASX real estate platform outperforms yet questions remain
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,715.32 | 0.39 | 0.00% |
| DAX 40 | 26,357.57 | 38.12 | 0.14% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,886.68 | 14.41 | -0.13% |
| HKSE | 25,902.16 | 234.13 | 0.91% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |